Evaluation of the Activated Whole Blood Clotting Time (ACT) in Vitro
- 1 September 1979
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 23 (3) , 239-244
- https://doi.org/10.1111/j.1600-0609.1979.tb02698.x
Abstract
The activated whole blood clotting time (Am was analyzed in vitro using blood samples from normal individuals and from patients with heart disease, scheduled for open heart surgery. The ACT was found to be normally distributed in a group of normal individuals with a mean d 135 sec. In patients with heart diseases, the average ACT was slightly shorter than in normal individuals. A linear relationship between ACT and heparin concentrations was established. Haemodilution and depletion of platelets did not significantly influence the ACT. When a clean venipuncture with disposable needles is used, ACT is a reliable, uncomplicated bedside technique by which heparinisation can be monitored.Keywords
This publication has 6 references indexed in Scilit:
- Activated F IX Concentrate (FEIBA) Used in the Treatment of Haemophilic Patients with Antibody to F VIIIActa Medica Scandinavica, 1978
- A Circulating Factor V Inhibitor: Possible Side Effect of Treatment with StreptomycinScandinavian Journal of Haematology, 1975
- Heparin therapy during extracorporeal circulationThe Journal of Thoracic and Cardiovascular Surgery, 1975
- Statistical Correlation and Heparin Sensitivity of Activated Partial Thromboplastin Time, Whole Blood Coagulation Time, and an Automated Coagulation TimeAmerican Journal of Clinical Pathology, 1973
- CONSUMPTION COAGULOPATHY IN CONGENITAL HEART-DISEASEThe Lancet, 1973
- Heparin Tolerance and the Plasma ProteinsScandinavian Journal of Clinical and Laboratory Investigation, 1961